Projected Prevalences of Age-Related Eye Diseases

Barbara E. K. Klein and Ronald Klein

Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Correspondence: Barbara E. K. Klein, Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, 610 N. Walnut Street, 409 WARF, Madison, WI 53726; kleinb@epi.ophth.wisc.edu.

Submitted: July 9, 2013
Accepted: July 12, 2013
Citation: Klein BEK, Klein R. Projected prevalences of age-related eye diseases. Invest Ophthalmol Vis Sci. 2013;54:ORSF14–ORSF17. DOI: 10.1167/iovs.13-12782

PURPOSE. To examine projections of age-related eye diseases in the United States for health care planning.

METHODS. Review of published scientific articles, census data, and unpublished research findings.

RESULTS. The numbers of cases of all age-related eye diseases are expected to rise in the coming years. These projections are primarily based upon population projections, but give little consideration to changes in health behaviors, racial/ethnic differences, environmental exposures, and changes in health care practices that may influence estimates of costs of actual health care burden.

CONCLUSIONS. Ongoing monitoring of trends in eye disease distribution is needed rather than projections based on old data that may be inadequate for generating reliable prediction models. There is a perpetual need to train new researchers with expertise in epidemiology, as the exigency for current prevalence estimates is crucial to maximize optimal visual health in the population.

Keywords: age-related eye diseases, prevalence, review

The prevalence of most eye diseases increases with age in virtually all populations. The Eye Diseases Prevalence Research Group (EDPRG) reported on data from ten different prevalence studies to estimate the prevalence of visual impairment and several specific eye diseases in persons 40 years of age or older to estimate the burden of these conditions in the United States (US) in 2000.1–6 These data and information from the National Health and Nutrition Examination Survey (NHANES) and other sources are compiled in another publication in this volume. In order to plan for future eye health care needs, projections for the future are desirable. It is the purpose of this paper to briefly describe current projections and potential limitations thereof.

MATERIALS AND METHODS

Study Population

Population projections to the year 2020 are from published projections from the EDPRG. For POAG, the projections are supplemented by information from 2011.7

Measurements

Estimates of prevalence were based on protocols that varied among the studies. Errors and systematic differences among studies are incorporated in the projections because there were no attempts to adjust prevalence data to uniform criteria for diagnostic labeling.

An example of the varying criteria for diagnostic labeling was given for glaucoma. In the EDPRG, six different sets of criteria were given for the studies.3 Some included disc photography, cutpoints varied for cup/disc diagnostic criteria, some studies included a cutoff for IOP, each used different techniques to assess visual fields, and some studies had subjective evaluation of components of glaucoma-related abnormalities, while others used a uniform set of criteria.

Statistical Analysis

The projected estimates from the EDPRG of the numbers and percentages of persons with the conditions were generated by applying the age, sex, and race/ethnicity of the prevalence data estimated for 2000 to projected middle series population projections for 2020.1–6 For the POAG estimates, Vajaranant and colleagues used prevalence estimates from the Baltimore Eye Survey, the Los Angeles Latino Eye Study, and the Tanjong Pagar Survey and applied these to the US Census population projections from 2011 to 2050 using middle series.7 Census population projections for 2000 to 2050 as well as methods for the 2012 updated projections were obtained from the US Census Bureau.8,9 Figures in this paper are reproduced from reports from the US Census Bureau8,10; the Table is a summary of projections that appeared in papers from the EDPRG.1–6

RESULTS

Predictions of disease prevalence depend upon projections of population changes by age and sex to the same date as the predictions aim for. For example, Figure 1 describes the middle series projections of the population by age and sex for 2012 to 2060 as calculated by the US Census Bureau.

The EDPRG projected prevalences of age-related eye diseases and visual functions from the year 2000 to 2020 based on projections of the US population to 2020 (Table). The estimated number of cases of each disorder was projected to increase over the 20-year period. They made the

Copyright 2013 The Association for Research in Vision and Ophthalmology, Inc.

www.iovs.org | ISSN 1552-5785

ORSF14

Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932982/ on 10/16/2017
assumption that prevalence would remain the same; the projected increase in number is a reflection of the increase in population size. However, projections should also account for shifting demographics of the population, as these may affect disease estimates. The US Census Bureau provided estimates by region of origin of foreign-born immigrants (Fig. 2).

The US Census Bureau projected that the non-Hispanic, white population will peak in 2024 and then fall by nearly 20.6 million to approximately 179 million by 2060, while the Hispanic population will increase to approximately 128.8 million, the black population will increase to approximately 61.8 million, and the Asian population will increase to approximately 34.4 million. Members of other racial/ethnic groups including American Indians, Alaskan Natives, Native Hawaiians, and other Pacific Islanders as well as those who identify themselves as being of two or more races/ethnicities will also increase. The older population will still be primarily non-Hispanic white in 2060 but this will change in subsequent years as the increasing numbers of persons of other races/ethnicities age.

Attempting to adjust for racial/ethnic shifts in demography, Vajaranant and colleagues projected the burden of POAG in 2050 based on the estimated prevalence in 2011. Their assumption was that more recent population projections accounting for shifts in race/ethnicity, especially for Hispanics and Asians, would improve upon the estimates made by the EDPRG. They estimated that there were 2.71 million persons with POAG in 2011 and that this number would increase to 7.32 million by 2050. However, population projections tend to be imperfect and the longer the time period in the forecast, the less accurate it tends to be. A comparison of US population projections made in 2008 and again in 2012 to the year 2050 illustrates this problem (Fig. 3). The estimated population projections differ by nearly 10%. Those data will be reflected in different predictions of estimates of disease prevalence.

There are other factors that predictions based solely on projected differences in population by demographic changes do not account for. There are temporal changes in the distribution of risk factors (e.g., changes in care of persons with diabetes, increasingly frequent cataract surgery, changes in socioeconomic status, access to care, and changes in environmental exposures, such as exposure to UV-B light). In addition, there appear to be temporal patterns in disease incidence, which are also likely to affect prevalence in

<table>
<thead>
<tr>
<th>Eye Disease</th>
<th>2000 N in Millions (%)</th>
<th>2020 N in Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract*</td>
<td>20.5 (17.2)</td>
<td>30.1</td>
</tr>
<tr>
<td>Pseudophakia†</td>
<td>6.1 (5.1)</td>
<td>9.5</td>
</tr>
<tr>
<td>Diabetic retinopathy</td>
<td>4.1 (3.4)</td>
<td>6.1</td>
</tr>
<tr>
<td>Vision-threatening diabetic retinopathy</td>
<td>0.9 (0.8)</td>
<td>1.4</td>
</tr>
<tr>
<td>Open-angle glaucoma</td>
<td>2.2 (1.9)</td>
<td>5.4</td>
</tr>
<tr>
<td>Late age-related macular degeneration</td>
<td>1.8 (1.5)</td>
<td>3.0</td>
</tr>
<tr>
<td>Large drusen</td>
<td>7.3 (6.1)</td>
<td>13.7</td>
</tr>
<tr>
<td>Blindness</td>
<td>0.9 (0.8)</td>
<td>1.6</td>
</tr>
<tr>
<td>Low vision</td>
<td>2.4 (2.0)</td>
<td>5.9</td>
</tr>
</tbody>
</table>

* Omits Mexican Americans.
† Includes Mexican Americans.
the future. For example, Klein and colleagues\textsuperscript{18} found a decrease in early AMD in more recent birth cohorts, which to date is not known to reflect decreases in risk factors.

**DISCUSSION**

Current projections of eye disease prevalence have been based largely on data that were collected many years ago and are restricted to a few eye conditions that are considered to be responsible for either visual loss (visual acuity poorer than 20/40 in the better seeing eye) or legal blindness (visual acuity poorer than 20/200 in the better seeing eye). These projections have been made for at best a handful of eye conditions. There are no known population projections for prevalence of dry eye, retinal vein occlusions, or many corneal conditions, which seem to be as prevalent as those for which projections have

**FIGURE 2.** Middle series projections of foreign-born immigration to the US by sending region: 2012 to 2060 (in thousands).\textsuperscript{8}

**FIGURE 3.** Projected population of the US: 2012 and 2050.\textsuperscript{10}
been made. These conditions should be considered when projecting disability from and remediation of age-related eye conditions.

Accurate estimates of prevalence and projections for future health care needs depend upon inclusion of all subgroups in the population. This implies systematic inclusion of samples of all persons including those currently undercounted and underserved. Access to care is likely to be improved by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. In addition, information about such improved access as well as education about the benefits of using such care needs to be implemented.

In summary, projections of prevalence are critical for planning for preventive and health care services with implications for function, quality of life, and costs; accurate projections are difficult to make and should be time-limited; every effort must be made to consider factors that the census does and any important known risk and preventive factors as well as temporal changes in them; frequent reassessment of outcomes and risk/protective factors is essential; and funding and encouragement for training of ocular epidemiologists is imperative to optimize planning for public health priorities to prevent or diminish the toll of age-related eye disease.

**Acknowledgments**

Supported by grants from the National Institutes of Health (EY06594 and EY016379) as well as an unrestricted grant from Research to Prevent Blindness, New York, New York. Disclosure: B.E.K. Klein, None; R. Klein, None

**References**